TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01281176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT02072707

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epicardial VT ablation
Description: Combined Epicardial and Endocardial VT Ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endocardial VT Ablation
Description: Endocardial Only VT ablation
Study: NCT03824483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: zanubrutinib (160mg by mouth BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: obinutuzumab (1000mg IVPB on Days 1\*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). \* On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC \>25,000 cells/ul or baseline lymph nodes \>5 cm diameter).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter.
Study: NCT01915498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Enasidenib tablets administered orally every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
Study: NCT02159651

Intervention type: DRUG
Intervention: tacrolimus
Description: oral

Intervention type: DRUG
Intervention: tacrolimus
Description: oral
Study: NCT01711814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral
Study: NCT02566759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Placebo
Description: TAK-831 placebo-matching oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Placebo
Description: TAK-831 placebo-matching oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Placebo
Description: TAK-831 placebo-matching oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Placebo
Description: TAK-831 placebo-matching oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Placebo
Description: TAK-831 placebo-matching oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Placebo
Description: TAK-831 placebo-matching oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Placebo
Description: TAK-831 placebo-matching oral suspension.
Study: NCT04212624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human retinal pigment epithelial (HuRPE) cell injection
Description: Human retinal pigment epithelial cell injection Dosage form and specifications: injection; 600,000 cells / branch (200μl), 1 million cells / branch (200μl), 2 million cells / branch (200μl) Transportation and storage: sealed, stored at 2-8 ° C, valid for 6 hours
Study: NCT02566759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Tablet
Description: TAK-831 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Tablet
Description: TAK-831 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Tablet
Description: TAK-831 tablet.
Study: NCT02247310

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaferon®, BAY 86-5046)
Description: Patients will be treated with Betaferon

Intervention type: DEVICE
Intervention: BETACONNECT
Description: Auto-injector device to support the injection of Betaferon
Study: NCT04330079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10mg once daily for 6 months.
Study: NCT02463058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise under hot and humid conditions protocol
Description: acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade \& 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (3 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (30 deg. centigrade \& 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously.
Study: NCT00027573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT04330079

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle modification
Description: lifestyle modification (diet and exercise) for 6 months
Study: NCT00027573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study: NCT01491321

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bee Venom Acupuncture Therapy
Description: Bee Venom 1:20,000 under BVA Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loxoprofen
Description: 60 mg/Tab, pers os 1Tab tid, for 3 weeks
Study: NCT00782353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANA598 200 mg bid or placebo
Description: ANA598 200 mg bid or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANA598 400 mg bid or placebo
Description: ANA598 400 mg bid or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANA598 800 mg bid or placebo
Description: ANA598 800 mg bid or placebo
Study: NCT01491321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loxoprofen
Description: 60 mg/Tab, pers os 1Tab tid, for 3 weeks

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% NaCl) under NS Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week
Study: NCT03734172

Intervention type: DIAGNOSTIC_TEST
Intervention: Sample collection
Description: Specimen collection
Study: NCT01237509

Intervention type: DEVICE
Intervention: Hypo device
Study: NCT00027573

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT01965015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the V-Wave inter-atrial shunt
Description: Percutaneous implantation of the V-Wave shunt by right heart catheterization (RHC) approach
Study: NCT00758225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients \> 45 kg: 900 mg/day (2 tablets 3 times a day)
Study: NCT02911610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: arthroscopy + volar plate
Description: surgery of wrist fractures with volar plate and added arthroscopy

Intervention type: DEVICE
Group type: OTHER
Intervention: Volar plate
Description: surgery of wrist fractures with volar plate
Study: NCT00595127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (10mg/kg/day x 4days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (30mg/m\^2/day x 5 days)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Description: TBI (450 cGY in a single fraction)
Study: NCT05647824

Intervention type: DEVICE
Intervention: Capillary Testing
Description: Testing Contour Fit BGMS with capillary blood

Intervention type: DEVICE
Intervention: Alternative Site Testing (AST)
Description: Testing Contour Fit BGMS using blood from alternative site

Intervention type: DEVICE
Intervention: Venous Testing
Description: Testing Contour Fit BGMS with venous blood
Study: NCT01850199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart telemedicine remote monitoring for gestational diabetes
Description: Intervention consists of a telemedicine platform which includes artificial intelligence tools to analyse glucose values and guarantee an optimal glucose control from the diagnosis of gestational diabetes to delivery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual management
Description: Usual care will be provided, including face-to-face visits
Study: NCT03228238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C and Vitamin E
Description: Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C and Vitamin E
Description: Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Atorvastatin calcium 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Atorvastatin calcium 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medication for variant angina
Description: Calcium Channel blocker or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medication for variant angina
Description: Calcium Channel blocker or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medication for variant angina
Description: Calcium Channel blocker or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medication for variant angina
Description: Calcium Channel blocker or NG
Study: NCT06360588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiologic Examination
Description: Undergo radiologic evaluation
Study: NCT00451425

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: motivational intervention in pregnancy
Description: Motivational program including individualized counseling on diet and physical activity
Study: NCT04072484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild hypoxia
Description: The subject will breathe a gas mixture containing 15% oxygen instead of 21% oxygen.
Study: NCT03826420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCF Supervision with Secure Confinement Sanctioning
Description: Parolees assigned to this group will, in the face of a violation, be given a sanction that involves secure confinement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCF Supervision with Work Release Sanctioning
Description: Parolees assigned to this group will, in the face of a violation, be given a sanction that involves work-release.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCF Supervision with GPS Supervision Sanctioning
Description: Parolees assigned to this group will, in the face of a violation, be given a sanction that involves GPS supervision.
Study: NCT03678012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol/Hydrogen peroxide
Description: 1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrogen Peroxide
Description: Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Water
Description: Sham solution (water; negative control). Each subject will use this product during one of three treatment periods in the crossover study design.
Study: NCT01556490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSphere
Description: Yttrium 90 microspheres
Study: NCT03245359

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short-term ON-Q
Description: single port, select-a-flow pump connected to saphenous nerve block catheter until medication in initial balls are depleted (usually 2-4 days)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short-term ON-Q
Description: single port, fixed flow pump connected to posterior knee catheter until medication in initial balls are depleted (usually 2-4 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short-term ON-Q
Description: Bupivacaine 0.125%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long-term ON-Q
Description: single port, select-a-flow pump connected to saphenous nerve block catheter until day 7 post-operative

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long-term ON-Q
Description: single port, fixed flow pump connected to posterior knee catheter until day 7 post-operative
Study: NCT04011878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined trabeculotomy trabeculectomy with mitomycin C
Description: Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases
Study: NCT01061554

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 oils from tri-glycerides
Description: Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 oils from tri-glycerides
Description: Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 oils from marine phospholipids
Description: Single-dose administration of approximately 5 grams of omega-3 oils from marine phospholipids
Study: NCT02289599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307 Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307 Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307 Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307 Matching Placebo
Study: NCT03245359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-term ON-Q
Description: Bupivacaine 0.125%
Study: NCT03741816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indirect pulp capping
Description: Indirect pulp capping is a procedure in which a material is placed on a thin partition of remaining carious dentin that, if removed might expose the pulp.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indirect pulp capping
Description: Indirect pulp capping is a procedure in which a material is placed on a thin partition of remaining carious dentin that, if removed might expose the pulp.
Study: NCT04303065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: It will be a short and descending course of oral dexamethasone: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: The preparation and conditioning of the placebo capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).
Study: NCT04698668

Intervention type: DEVICE
Intervention: fusion imaging
Description: To drain a pancreatic fluid collection through the assitance of the CT-scan image that is superimposed on the radiological field
Study: NCT04076982

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mung bean protein
Description: Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control biscuit
Description: Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
Study: NCT02492152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study group
Description: Dianatal
Study: NCT00261859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BNI
Description: behavioral- brief intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BNI
Description: behavioral- brief intervention
Study: NCT04612465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASC
Description: Injection of ASC(Autologous Adipose-derived Mesenchymal Stem Cells) to Crohn's Fistula.~The ASC injection dose is about 1x10\^7 cells of ASC per 1cm\^2 of the surface area of the fistula, and the additional injection dose is 1.5 times the initial injection dose. and up to 30% of the ASC injection dose is administered in combination with Fibringlu.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fibringlue
Description: Injection of Fibringlue to Crohn's Fistula. The Fibringlu injection dose is given the size of the fistula that is fill the entire fistula, and the additional injection dose is the same.
Study: NCT03381898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Exercise, speech therapy, medication management
Description: Telehealth exercise once per week, speech therapy 4 times per week, medication management once per week
Study: NCT02989922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
Study: NCT02289599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307 Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307 Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307 Matching Placebo
Study: NCT00711087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX-A
Description: Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Group 2-sham saline injections on both Day 0 and Day 90.
Study: NCT01753999

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPAP
Description: Use of the REMstar Auto A-Flex in standard CPAP therapy mode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP - Flex
Description: Use of Philips Respironics REMstar Auto A-Flex in C-Flex mode